- Home
- DEC vs CERT Comparison
DEC vs CERT Comparison
Compare DEC & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DEC | CERT |
|---|---|---|
| Founded | 2001 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Retail: Computer Software & Peripheral Equipment |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DEC | CERT |
|---|---|---|
| Price | $14.78 | $7.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $21.40 | $12.22 |
| AVG Volume (30 Days) | 628.2K | ★ 3.1M |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | ★ 7.97% | N/A |
| EPS Growth | ★ 311.06 | 87.50 |
| EPS | ★ 4.58 | N/A |
| Revenue | ★ $1,829,142,000.00 | $418,838,000.00 |
| Revenue This Year | $18.28 | $5.05 |
| Revenue Next Year | N/A | $5.73 |
| P/E Ratio | $3.17 | ★ N/A |
| Revenue Growth | ★ 141.54 | 8.75 |
| 52 Week Low | $10.08 | $6.04 |
| 52 Week High | $16.86 | $15.38 |
Technical Indicators
Market Signals| Indicator | DEC | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 66.62 | 42.40 |
| Support Level | $14.01 | $6.04 |
| Resistance Level | $15.49 | $11.53 |
| Average True Range (ATR) | 0.48 | 0.40 |
| MACD | 0.15 | 0.14 |
| Stochastic Oscillator | 83.30 | 68.92 |
Price Performance
Historical ComparisonAbout DEC Diversified Energy Company plc
Diversified Energy Co is an independent energy company focused on natural gas and liquids production, transportation, marketing and well retirement, located within the Appalachian and Central regions of the United States. Its principal focus is on enhancing producing wells, not drilling new wells, thereby allowing it to optimise PDP revenues and reduce costs. The company derives revenues from the sale of oil, natural gas and natural gas liquids.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.